Urticaria chronic

2 trials MedDRA PT
2 Registered trials
0 Recruiting
1 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 1 substance
Phase II: 1 Phase I/II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

1 trial
  • Jasper Therapeutics Inc. Commercial
    BRIQUILIMAB
    2024-517830-17-00 1 country 2025 n=45
    Ended

Phase I/II

1 trial
  • Jasper Therapeutics Inc. Commercial
    BRIQUILIMAB
    2023-507534-24-00 1 country 2024 n=20
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Jasper Therapeutics Inc. Commercial 2 Phase II, Phase I/II 0
New trials by year
2024
1
2025
1
← All indication landscapes